Lombardy Region: seven years of breast cancers screening before, during and after the SARS-CoV-2 pandemic
Keywords:
Screening Program; Cancer Prevention; Healthcare System organizationAbstract
Background. Breast cancer represents the most common form of neoplasm in women, with an estimated 685,000 deaths annually. In this regard, screening programmes represent one of the most effective intervention tools in the field of cancer prevention. The aim of this study is to analyse and describe the key performance indicators of the screening programmes in Lombardy from 2016 to 2022.
Study design. Descriptive temporal analysis study.
Methods. The data pertaining to the screening campaign were subjected to analysis, with the results broken down according to the following criteria: individual province, age group eligible for screening, and campaign year. For each campaign, the data pertaining to the population subjected to screening, as well as the data concerning the rate of cancers identified during the campaign, were subjected to analysis.
Results. For the three age groups, a substantial overlap in call and campaign adherence rates can be observed, with stable values between 2016 and 2019, followed by a significant decline in the 2020 campaign associated with the impact of the pandemic on prevention activities, including cancer screening campaigns. The data for 2021 and 2022 indicate a reversal of the decline in adherence and call rates, particularly in the 45–49 age group, which exhibited an increase of approximately 300% in the call rate between 2021 and 2020. Moreover, the categorization of the provinces into urban, mountainous and rural provinces demonstrates an overlap in the admission rates between the three areas in the different years.
Conclusions. Despite the existence of mammography screening campaigns for more than 20 years, adherence rates in the Lombardy region remain below the targets set out in Europe’s Beating Cancer Plan. In this regard, the observed variations, particularly during the period of the pandemic and in the subsequent post-pandemic period, provide an opportunity to rethink the organization of screening campaigns in order to increase adherence and effectiveness.
References
1. World Health Organization (WHO). Breast Cancer [Internet]. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer [Last accessed: 2024 Nov 14].
2. Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022 Feb 1;95(1130):20211033. doi: 10.1259/bjr.20211033. Epub 2021 Dec 14. PMID: 34905391; PMCID: PMC8822551.
3. Associazione Italiana di Oncologia Medica (AIOM), Associazione Italiana Registri Tumori (AIRT), Fondazione AIOM, Osservatorio Nazionale Screening (ONS), PASSI (Progressi delle Aziende Sanitarie per la Salute in Italia), et al. I numeri del cancro in Italia. 2022.
4. Lauby-Secretan B, Scoccianti C, Loomis D, Benbrahim-Tallaa L, Bouvard V, Bianchini F, et al. Breast-Cancer Screening-Viewpoint of the IARC Working Group. N Engl J Med. 2015 Jun 11;24(372):2353-8. doi: 10.1056/NEJMsr1504363. Epub 2015 Jun 3. PMID: 26039523.
5. Coldman A, Phillips N, Wilson C, Decker K, Chiarelli AM, Brisson J, et al. Pan-Canadian study of mammography screening and mortality from breast cancer. J Natl Cancer Inst. 2014 Oct 1;106(11):261. doi: 10.1093/jnci/dju261. PMID: 25274578.
6. Australian Institute of Health and Welfare. BreastScreen Australia monitoring report 2008-2009. Canberra: Australian Institute of Health and Welfare; 2011.
7. Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 2012 Jun;36(3):237-48. doi: 10.1016/j.canep.2012.02.007. Epub 2012 Mar 27. PMID: 22459198.
8. Njor S, Nyström L, Moss S, Paci E, Broeders M, Segnan N, et al. Breast cancer mortality in mammographic screening in Europe: A review of incidence-based mortality studies. J Med Screen. 2012 Sep;19(Suppl 1):33-41. doi: 10.1258/jms.2012.012080. PMID: 22972809.
9. Zielonke N, Kregting LM, Heijnsdijk EAM, Veerus P, Heinävaara S, McKee M, de Kok IMCM, et al. The potential of breast cancer screening in Europe. Int J Cancer. 2021 Jan 15;148(2):406-18. doi: 10.1002/ijc.33204. Epub 2020 Jul 30. PMID: 32683673; PMCID: PMC7754503.
10. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013 Jun 11;108(11):2205-40. doi: 10.1038/bjc.2013.177. Epub 2013 Jun 6. PMID: 23744281; PMCID: PMC3693450.
11. National Healthcare System (NHS). NHS population screening: access and order leaflets [Internet]. 2018. Available from: https://www.gov.uk/guidance/how-to-order-population-screening-leaflets [Last accessed: 2024 Nov 14].
12. National Healthcare System (NHS). Breast screening: programme overview [Internet]. 2015. Available from: https://www.gov.uk/guidance/breast-screening-programmeoverview [Last accessed: 2024 Nov 14].
13. European Commission. Screening ages and frequencies [Internet]. 2023. Available from: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Cancer_screening_statistics [Last accessed: 2024 Nov 14].
14. Group of Chief Scientific Advisors, European Commission, Directorate-General for Research and Innovation. Cancer screening in the European Union Independent Expert Report [Internet]. Brussels; 2022.
15. Repubblica Italiana. Decreto del Presidente del Consiglio dei Ministri 12 gennaio 2017. Definizione e aggiornamento dei livelli essenziali di assistenza, di cui all’articolo 1, comma 7, del decreto legislativo 30 dicembre 1992, n. 502. GU Serie Generale n. 65 del 18 marzo 2017 (Suppl Ord n. 15). Available from: https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2017-03-18&atto.codiceRedazionale=17A02015&elenco30giorni=false [Last accessed: 2024 Nov 14].
16. Regione Lombardia. Decreto della Direzione Generale Welfare 3 aprile 2017, n. 3711. Aggiornamento fasce eta’ target dei programmi di screening oncologici per la prevenzione del tumore della mammella e del colon retto. Available from: https://www.regione.lombardia.it/wps/portal/istituzionale/HP/DettaglioServizio/servizi-e-informazioni/enti-e-operatori/sistema-welfare/promozione-della-salute/screening-prevenzione-tumori/ddg2017-3711-aggiornamento-fasce-eta-screening [Last accessed: 2024 Nov 14].
17. Battisti F, Falini P, Gorini G, Sassoli de Bianchi P, Armaroli P, Giubilato P, et al. Cancer screening programmes in Italy during the COVID-19 pandemic: an update of a nationwide survey on activity volumes and delayed diagnoses. Ann Ist Super Sanita. 2022 Jan-Mar;58(1):16-24. doi: 10.4415/ANN_22_01_03. PMID: 35324470.
18. Battisti F, Mantellini P, Falini P, Ventura L, Giordano L, Saguatti G, et al. Key performance indicators of breast cancer screening programmes in Italy, 2011-2019. Ann Ist Super Sanita. 2022 Oct-Dec;58(4):244-253. doi: 10.4415/ANN_22_04_04. PMID: 36511195.
19. Iragorri N, Spackman E. Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis. Public Health Rev. 2018 Jul 13;39:17. doi: 10.1186/s40985-018-0093-8. PMID: 30009081; PMCID: PMC6043991.
20. Ministero della Salute. Screening per il cancro del seno [Internet]. 2023. Available from: https://www.salute.gov.it/portale/tumori/dettaglioContenutiTumori.jsp?lingua=italiano&id=5542&area=tumori&menu=screening [Last accessed: 2024 Nov 14].
21. Regione Lombardia. Legge Regionale 30 dicembre 2009, n. 33. Testo unico delle leggi regionali in materia di sanità. BURL n. 52 del 31 dicembre 2009 (3o Suppl Ord). Available from: https://normelombardia.consiglio.regione.lombardia.it/normelombardia/Accessibile/main.aspx?iddoc=lr002009123000033&view=showdoc [Last accessed: 2024 Nov 14].
22. Istituto Nazionale di Statistica (ISTAT). 2023. Indicatori Demografici. Available from: http://dati.istat.it/Index.aspx?DataSetCode=DCIS_INDDEMOG1# [Last accessed: 2024 Nov 14].
23. Australian Institute of Health and Welfare. Breast Screen Australia monitoring report 2006-2007 and 2007-2008 (full publication; 21/7/2010 edition); 2006. Available from: https://www.aihw.gov.au/getmedia/3a4594c3-1a9b-4fcb-9-d1b-5be1eeaa9011/11751.pdf?v=20230605165037&inline=true [Last accessed: 2024 Nov 14].
24. Loewen OK, Sandila N, Shen-Tu G, Vena JE, Yang H, Patterson K, et al. Patterns and predictors of adherence to breast cancer screening recommendations in Alberta’s Tomorrow Project. Prev Med Rep. 2022 Nov 15;30:102056. doi: 10.1016/j.pmedr.2022.102056. PMID: 36531110; PMCID: PMC9747638.
25. Israel Cancer Association (ICA). Breast Cancer [Internet]. 2021. Available from: https://en.cancer.org.il/template_e/default.aspx?PageId=7749 [Last accessed: 2024 Nov 14].
26. Genovese C, Squeri R, Alessi V, Conti A, D’Amato S, Mazzitelli F, et al. Adherence to the three Italian screening in a sample of women (and men) in the Southern Italy. Clin Ter. 2021 Jan 1;172(1):e75-e79. doi: 10.7417/CT.2021.2287. PMID: 33346333.
27. Sarkar S, Kaur T, Ranjan P, Sahu A, Kumari A. Tools for the evaluation of the psychological impact of COVID-19: A practical guide for Family physicians and Primary Care Practitioners. J Family Med Prim Care. 2021 Apr;10(4):1503-1507. doi: 10.4103/jfmpc.jfmpc_2107_20. Epub 2021 Apr 29. PMID: 34123881; PMCID: PMC8144778.
28. Agorastos A, Tsamakis K, Solmi M, Correll CU, Bozikas VP. The need for holistic, longitudinal and comparable, real-time assessment of the emotional, behavioral and societal impact of the COVID-19 pandemic across nations. Psychiatriki. 2021 Apr 19;32(1):15-18. English, Greek, Modern. doi: 10.22365/jpsych.2021.010. Epub 2021 Mar 8. PMID: 33759804.
29. Perrone PM, Biganzoli G, Lecce M, Campagnoli EM, Castrofino A, Cinnirella A, et al. Influenza Vaccination Campaign during the COVID-19 Pandemic: The Experience of a Research and Teaching Hospital in Milan. Int J Environ Res Public Health. 2021 May 30;18(11):5874. doi: 10.3390/ijerph18115874. PMID: 34070763; PMCID: PMC8198860.
30. Altobelli E, Rapacchietta L, Angeletti PM, Barbante L, Profeta FV, Fagnano R. Breast cancer screening programmes across the WHO European region: Differences among countries based on national income level. Int J Environ Res Public Health. 2017 Apr 23;14(4):452. doi: 10.3390/ijerph14040452. PMID: 28441745; PMCID: PMC5409652.
31. Petkeviciene J, Ivanauskiene R, Klumbiene J. Sociodemographic and lifestyle determinants of non-attendance for cervical cancer screening in Lithuania, 2006–2014. Public Health. 2018 Mar;156:79-86. doi: 10.1016/j.puhe.2017.12.014. Epub 2018 Feb 3. PMID: 29408192.
32. Richard A, Rohrmann S, Schmid SM, Tirri BF, Huang DJ, Güth U, et al. Lifestyle and health-related predictors of cervical cancer screening attendance in a Swiss population-based study. Cancer Epidemiol. 2015 Dec 1;39(6):870-6. doi: 10.1016/j.canep.2015.09.009. Epub 2015 Nov 9. PMID: 26651449.
33. Kumar P, Kumar S, Baruah CC. Breast cancer management. Biomed Pharmacother. 2013 Oct;67(8):685-6. doi: 10.1016/j.biopha.2013.06.010. Epub 2013 Jul 10. PMID: 23906758.
34. Welch HG, Prorok PC, O’Malley AJ, Kramer BS. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. N Engl J Med. 2016 Oct 13;375(15):1438-1447. doi: 10.1056/NEJMoa1600249. PMID: 27732805.
35. Møller MH, Lousdal ML, Kristiansen IS, Støvring H. Effect of organized mammography screening on breast cancer mortality: A population-based cohort study in Norway. Int J Cancer. 2019 Feb 15;144(4):697-706. doi: 10.1002/ijc.31832. Epub 2018 Oct 22. PMID: 30144028.
36. Niell BL, Freer PE, Weinfurtner RJ, Arleo EK, Drukteinis JS. Screening for Breast Cancer. Radiol Clin North Am. 2017 Nov;55(6):1145-1162. doi: 10.1016/j.rcl.2017.06.004. PMID: 28991557.
37. Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA. Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR. J Am Coll Radiol. 2018 Mar;15(3 Pt A):408-414. doi: 10.1016/j.jacr.2017.11.034. Epub 2018 Jan 19. PMID: 29371086.
38. Cooper K, Siefert A, Weinreb J. Skills Beyond the Reading Room: Training in Innovation and Collaboration at a Radiology Hackathon. J Am Coll Radiol. 2018 Mar;15(3 Pt A):466-468. doi: 10.1016/j.jacr.2017.11.034. Epub 2018 Jan 19. PMID: 29371086.
39. Guiberteau MJ, Oates ME. Counterpoint: Nuclear Medicine’s Decline: Radiology Is the Solution, Not the Problem. J Am Coll Radiol. 2018 Mar;15(3 Pt A):387-389. doi: 10.1016/j.jacr.2017.11.029. PMID: 29502650.
40. Kovacs MD, Sheafor DH, Thacker PG, Hardie AD, Costello P. Metrix Matrix: A Cloud-Based System for Tracking Non-Relative Value Unit Value-Added Work Metrics. J Am Coll Radiol. 2018 Mar;15(3 Pt A):415-421. doi: 10.1016/j.jacr.2017.10.028. Epub 2017 Dec 24. PMID: 29279292.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Elena Maria Ticozzi, Pier Mario Perrone, Silvia Deandrea, Marina Tanious, Danilo Cereda, Silvana Castaldi (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.